Scarica l'app Stockscreener
43.71
3.40%
1.4771
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$42.23
Aprire:
$42.28
Volume 24 ore:
6.25M
Relative Volume:
0.54
Capitalizzazione di mercato:
$17.08B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-5.0065
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+3.98%
1M Prestazione:
+4.39%
6M Prestazione:
+55.84%
1 anno Prestazione:
+32.36%
Intervallo 1D:
$41.97
$45.07
Intervallo di 1 settimana:
$36.66
$45.07
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
43.71 | 16.50B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.38 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.88 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
849.36 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
334.44 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
356.29 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
MRNA: RBC Capital Maintains Rating and Raises Price Target | MRN - GuruFocus
Moderna (MRNA) Sees Bullish Activity with Increased Call Options - GuruFocus
Moderna's COVID-19 Vaccine mNEXSPIKE Receives EU Marketing Authorization - Intellectia AI
Moderna Stock Rises After EU Marketing Authorization For mNEXSPIKE - Benzinga
Moderna (MRNA) Price Target Raised to $35 by Evercore ISI Group - GuruFocus
Bernstein Adjusts Price Target on Moderna to $45 From $35, Maintains Market Perform Rating - marketscreener.com
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline - FinancialContent
RBC raises Moderna stock price target to $30 on pipeline progress - Investing.com Australia
RBC Capital Adjusts Price Target on Moderna to $30 From $25, Maintains Sector Perform Rating - marketscreener.com
Moderna Gets Approval for COVID Vaccine From European Commission - marketscreener.com
Moderna receives European Commission marketing authorization for Covid-19 vaccine Mnexspike - marketscreener.com
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE - Weatherford Democrat
New Moderna COVID shot shows 9.3% edge in trial, now cleared in Europe - Stock Titan
Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90 - simplywall.st
Analyst recommendations: Accenture, Dollar Tree, DraftKings, Moderna, Walmart… - marketscreener.com
Editorial: Letting disease win — FDA’s dangerous refusal of Moderna’s new mRNA flu vaccine - The Daily Gazette
Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push - BioSpace
To save seniors’ lives, Trump must stomp on this deadly anti-vax call - New York Post
Moderna Q4 2025 net loss narrows; revenue drops 30% - AlphaStreet News
US FDA Refuse-To-File Letters Hit The Big Time With Moderna’s Flu Vaccine - Citeline News & Insights
Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait - BioSpace
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders - TradingView
Tobam Lowers Holdings in Moderna, Inc. $MRNA - MarketBeat
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
Is Moderna (MRNA) Pricing Reflecting Potential After Sharp Multi‑Year Share Price Pullback? - Yahoo Finance
This Is What Destroying the Vaccine Market Looks Like - The Bulwark
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Lisa Jarvis: Moderna’s flu shot ordeal hurts innovation — and public health - The Daily Gazette
Can Moderna Inc. weather a recessionEarnings Recap Report & Technical Buy Zone Confirmations - mfd.ru
Moderna (MRNA) Tops Q4 Estimates Despite Regulatory Setback - GuruFocus
U.S. vaccine policy under RFK Jr. challenged in court (PFE) - Seeking Alpha
Earnings Scorecard: Healthcare sector shows strong top-line pulse - Seeking Alpha
Moderna looks outside US for growth after FDA’s flu shot refusal - WTVB
MRNA Q4 Deep Dive: New Vaccines, Cost Controls, and Pipeline Milestones Shape Outlook - Finviz
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - TheDailyJournal.com
CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot - The Cancer Letter
Moderna CEO Worries About Drug Development Overall After US FDA mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results - FinancialContent
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend - FXEmpire
Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron's
Moderna Has A Few Words For The FDA After mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Moderna: Q4 Earnings Snapshot - theheraldreview.com
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial ... By GuruFocus - Investing.com Canada
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know - Yahoo! Finance Canada
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial Challenges - GuruFocus
Moderna (MRNA) Faces Challenges Amid Renewed Interest in Biotech Sector - GuruFocus
Moderna Challenges FDA After Flu Shot Review Refusal, 26% Covid Drop - GuruFocus
Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic... - Proactive financial news
Moderna's mRNA Technology Has Potential Across Vaccines, Oncology, and Rare Diseases - Morningstar
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results, Beats Estimates By $0.68 EPS - MarketBeat
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
0.42%
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):